Filing Details
- Accession Number:
- 0001567619-21-001343
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-01-21 17:11:22
- Reporting Period:
- 2021-01-19
- Accepted Time:
- 2021-01-21 17:11:22
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1656634 | Gritstone Oncology Inc. | GRTS | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1754287 | Raphael Rousseau | C/O Gritstone Oncology, Inc. 5959 Horton Street, Suite 300 Emeryville CA 94608 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-01-19 | 20,000 | $0.76 | 20,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-01-19 | 20,000 | $17.53 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-01-20 | 10,000 | $0.76 | 10,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-01-20 | 10,000 | $25.07 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2021-01-19 | 20,000 | $0.00 | 20,000 | $0.76 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2021-01-20 | 10,000 | $0.00 | 10,000 | $0.76 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 135,326 | 2027-05-17 | No | 4 | M | Direct | |
| 125,326 | 2027-05-17 | No | 4 | M | Direct |
Footnotes
- The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction.
- Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $15.00 to $20.04 per share. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.00 to $25.17 per share. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The stock option vests and becomes exercisable with respect to 25% of the total number of shares on April 17, 2018. The remaining shares vest and become exercisable in equal monthly installments over the following 36 months.
Billionaire Hedge Funds
